Loading...

PE anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_GK1dot5_PE_021706
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 1_GK1dot5_PE_021706
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 2_GK15_PE_CD4_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (solid line) or rat IgG2b, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100407 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100408 200 µg 58€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  2. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  3. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  4. Friess MC, et al. 2022. Cell Rep. 38:110334. PubMed
  5. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  6. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  7. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  8. Palacios-Arreola M, et al. 2017. Sci Rep. 10.1038/s41598-017-10135-1. PubMed
  9. Man SM et al. 2016. Cell. 167(2):382-396 . PubMed
  10. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  11. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  12. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  13. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  14. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  15. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  16. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  17. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  18. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  19. Willinger T, et al. 2014. J Exp Med. 211:685. PubMed
  20. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  21. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  22. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  23. Zhang L, et al. 2020. Front Oncol. 1.243055556. PubMed
  24. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  25. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  26. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  27. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  28. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  29. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  30. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  31. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  32. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  33. Leech JM, et al. 2020. Cell Host & Microbe. 26(6):795-809.e5.. PubMed
  34. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  35. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  36. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  37. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  38. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  39. Yuan X, et al. 2019. JCI Insight. 4:e124317. PubMed
  40. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  41. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  42. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  43. Antunes KH, et al. 2022. Front Immunol. 13:867022. PubMed
  44. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  45. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  46. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  47. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  48. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  49. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  50. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  51. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  52. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  53. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  54. Collin R, et al. 2014. J Immunol. 193:3503. PubMed
  55. Karki R, et al. 2020. JCI Insight. 5:00. PubMed
  56. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  57. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  58. Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed
  59. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  60. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  61. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  62. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  63. Lv F, et al. 2022. iScience. 25:103639. PubMed
  64. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  65. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  66. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  67. Huang YL, et al. 2021. Commun Biol. 4:229. PubMed
  68. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  69. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  70. Yang H, et al. 2022. Nutrients. 14:. PubMed
  71. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  72. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  73. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  74. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  75. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  76. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  77. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  78. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  79. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  80. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  81. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  82. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  83. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  84. Yang C, et al. 2013. Proc Natl Acad Sci U S A. 111:109. PubMed
  85. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  86. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  87. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  88. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  89. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  90. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  91. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  92. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  93. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  94. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  95. Cho K, et al. 2021. iScience. 24:103117. PubMed
  96. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  97. Colombo M, et al. 2022. iScience. 25:105042. PubMed
  98. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  99. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  100. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  101. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  102. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  103. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  104. Du J, et al. 2018. AMB Express. 8:158. PubMed
  105. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
  106. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  107. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  108. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
  109. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  110. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  111. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  112. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  113. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  114. Nakamura Y, et al. 2015. Infect Immun . 83:671. PubMed
  115. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  116. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  117. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  118. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  119. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  120. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  121. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  122. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  123. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  124. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  125. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  126. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  127. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  128. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  129. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  130. Zhang H, et al. 2009. Invest Ophthalmol Vis Sci. 50:2653. PubMed
  131. Chen S, et al. 2022. iScience. 25:105176. PubMed
  132. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  133. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  134. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
  135. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  136. Liu Y, et al. 2019. Sci Rep. 9:18970. PubMed
  137. Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed
  138. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  139. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  140. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  141. Deliyannis G, et al. 2021. JCI Insight. 6:. PubMed
  142. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  143. Mahlios J, Zhuang Y 2011. Mol Immunol. 49:227. PubMed
  144. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  145. Klose R, et al. 2016. Nat Commun. 7:12528. PubMed
  146. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  147. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  148. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  149. Li H, et al. 2022. iScience. 25:104481. PubMed
  150. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  151. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  152. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  153. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  154. Gao P, et al. 2021. Nat Commun. 1194:12. PubMed
  155. Yomogida K, et al. 2013. Biochem Biophys Res Commun. 434:263. PubMed
  156. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  157. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  158. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  159. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  160. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  161. Gawish R, et al. 2022. Elife. 11:. PubMed
  162. Kong IY, et al. 2020. Cell Rep. 33:108290. PubMed
  163. Fu W, et al. 2020. J Immunol Res. 8820355:2020. PubMed
  164. Mesin L, et al. 2020. Cell. 180(1):92-106.e11.. PubMed
  165. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  166. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  167. Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed
  168. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  169. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  170. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  171. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  172. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  173. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  174. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  175. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  176. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  177. Sun J, et al. 2012. Arterioscler Thromb Vasc Biol. 32:15:00. PubMed
RRID
AB_312692 (BioLegend Cat. No. 100407)
AB_312693 (BioLegend Cat. No. 100408)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV™ 395 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account